1. Inicio
  2. Proyectos y Estudios
  3. Efficacy, safety and patient-reported outcomes of peptide receptor radionuclide therapy with 177Lu-edotreotide compared to everolimus in somatostatin receptor positive neuroendocrine tumors of the lung and thymus".

Efficacy, safety and patient-reported outcomes of peptide receptor radionuclide therapy with 177Lu-edotreotide compared to everolimus in somatostatin receptor positive neuroendocrine tumors of the lung and thymus".

Datos básicos

Código:
GETNE-T2217
Protocolo:
GETNE-T2217
EUDRACT:
2022-502154-13-00
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2023
Año de finalización:
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

GETNE (NO USAR)

Resultados del Ensayo Clínico

[[Tranaslated article]]Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years.

López DF; (...); Ortiz-Romero, P. L.

Article. 10.1016/j.ad.2022.11.013. 2023

  • Open Access.

[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.

Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin

Article. 10.1016/j.farma.2024.08.002. 2024

  • Open Access.

[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024

  • Open Access.

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations - Data from 552 cases in the SEPTRALU registry

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2023


A Gadolinium(III) Complex Based on Pyridoxine Molecule with Single-Ion Magnet and Magnetic Resonance Imaging Properties.

Orts-Arroyo, Marta; (...); Martinez-Lillo, Jose

Article. 10.3390/ijms25042112. 2024

  • Open Access.

Alternatives of the pelvic sentinel lymph node migration pathway in early ovarian cancer: the simplest the best.

Lago, Victor; (...); Domingo, Santiago

Article. 10.1136/ijgc-2023-004912. 2023

  • Open Access.

Amyloid brain-dedicated PET images can diagnose Alzheimer's pathology with Centiloid Scale.

Gandia-Ferrero MT; (...); Martí-Bonmatí L

Article. 10.1016/j.ejmp.2024.103345. 2024


Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.

Pérez-Alenda S; (...); Núñez-Cortés R

Article. 10.1111/hae.14988. 2024

  • Open Access.

Clinical experience of whole body and tumour dosimetry of 131-I-mIBG treatment for pediatric patients

Espallardo, I. Torres; (...); Prado-Wohlwend, S.

Meeting Abstract. 2023


ComBat harmonization in different PET imaging scenarios

Gandia-Ferrero, M.; (...); Marti-Bonmati, L.

Meeting Abstract. 2023


Correlation Between Clinical Characteristics And Effective Washout Time In Patients Treated With High Radioiodine Activities

Guerrero Calatayud, C.; (...); Bello Arques, P.

Meeting Abstract. 2023


Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.

Megias-Vericat, Juan E; (...); Yan, Songkai

Article. 10.1080/13696998.2025.2474886. 2025


CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.

Sanchis-Pascual, David; (...); Merino-Torres, Juan Francisco

Article. 10.3390/cancers16101799. 2024

  • Open Access.

Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024


Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A multicenter study

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2023


Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study.

Mitjavila, Mercedes; (...); Carmona-Bayonas, Alberto

Article. 10.1007/s00259-023-06166-8. 2023

  • Open Access.

Free automatic software for quality assurance of computed tomography calibration, edges and radiomics metrics reproducibility.

Saborido-Moral, Juan D.; (...); Carles, Montserrat

Article. 10.1016/j.ejmp.2023.103153. 2023

  • Open Access.

Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.

Calsina, Bruna; (...); Robledo, Mercedes

Article. 10.1038/s41467-023-36769-6. 2023

  • Open Access.

Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study

Del Olmo-Garcia, M.; (...); Argente Pla, M.

Meeting Abstract. 2024


Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.3390/cancers15082267. 2023

  • Open Access.

Just a matter of weight? Final results from NUTRIGETNE study in patients with Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

Pla, Argente M.; (...); Del Olmo-Garcia, M.

Meeting Abstract. 2024


MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma.

Monteagudo M; (...); Robledo M

Article. 10.1016/j.beem.2024.101931. 2024

  • Open Access.

Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.

Rodríguez MA; (...); Chimeno-Hernández A

Article. 10.1016/j.thromres.2024.109181. 2024

  • Open Access.

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

  • Open Access.

Nutritional status of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain - NUTRIGETNE study

Hernandez-Rienda, L.; (...); Del Olmo-Garcia, M.

Meeting Abstract. 2023


Objective Image Quality Comparison Between Brain-Dedicated PET and PET/CT Scanners.

Gandia-Ferrero MT; (...); Martí-Bonmatí L

Article. 10.1007/s10916-023-01984-7. 2023


Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Prediction of patient progression-free survival with 177Lu-DOTATATE in clinical practice: NEPTUNESEPTRALU model for patient selection

Mitjavila Casanovas, M.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2024


Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) - Data from the national registry SEPTRALU

Bello, P.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2023


Proposal of a short acquisition protocol for 18F-DOPA imaging in brain tumors:preliminary results

Orrego, N.; (...); Bello-Arques, P.

Meeting Abstract. 2024


Radio theranostics in paragangliomas and pheochromocytomas

Wohlwend, S. Prado, Arques, P. Bello

Article. 10.1016/j.remn.2024.500017. 2024

  • Open Access.

Radio theranostics in paragangliomas and pheochromocytomas.

Wohlwend SP, Arques PB

Article. 10.1016/j.remnie.2024.500017. 2024

  • Open Access.

Relationship between neuroimaging and emotion recognition in Mild Cognitive Impairment patients.

Gandia-Ferrero, Maria Teresa; (...); Marti-Bonmati, Luis

Article. 10.1016/j.bbr.2023.114844. 2024


Retreatment PRRT with 177Lu-DOTATATE in patients with progressive neuroendocrine neoplasm: Spanish clinical experience from national registry

Mitjavila Casanovas, M.; (...); Hernando, J.

Meeting Abstract. 2024


Sequential treatment of High-risk Neuroblastoma combining I-131 MIBG high-dose and Topotecan. First experience

Orrego, N.; (...); Bello-Arques, P.

Meeting Abstract. 2023


State of the art and future perspectives of new radionuclides in Nuclear Medicine.

Rosales, J J; (...); Quincoces, G

Article. 10.1016/j.remnie.2025.500082. 2025


The NETFIT trial: Smart wearable medical devices to assess the quality of life of patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Molina Cerrillomd, Javier; (...); Capdevila, Jaume

Meeting Abstract. 2023


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Uncovering the genomic profiling of metastatic pheochromocytomas and paragangliomas: Leveraging plasma circulating tumor DNA for comprehensive genetic characterisation and monitoring

Arenillas, Lallana C.; (...); Toledo, R. A.

Meeting Abstract. 2024


Update on iodine-refractory differentiated thyroid carcinoma

Casas, E. Abou Jokh; (...); Casas, J. A. Vallejo

Article. 10.1016/j.remn.2023.06.005. 2023


Update on iodine-refractory differentiated thyroid carcinoma.

Jokh Casas, E A; (...); Vallejo Casas, J A

Article. 10.1016/j.remnie.2023.07.003. 2023


Y-90 PET/MR imaging optimization with a Bayesian penalized likelihood reconstruction algorithm.

Calatayud-Jordan, Jose; (...); Torres-Espallardo, Irene

Article. 10.1007/s13246-024-01452-7. 2024

  • Open Access.

Campos de estudio

Compartir